In one paragraphArticle in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
8 authors.
Preeti GaraiDepartment of Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0002-3713-6441 Sophia H NozickDepartment of Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0002-0791-6340 Caroline C JozefczykMidwestern University College of Pharmacy, Downers Grove Campus, Downers Grove, Illinois, USA.
J Nicholas O'DonnellDepartment of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA.ORCID 0000-0001-5184-1385 Egon A OzerDivision of Infectious Diseases, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0002-7131-3691 Alan R HauserDepartment of Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0003-4596-7939 Funding
Technology CoreU19AI135964 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI JUSTIN B. STARREN · 2018 to 2026
$24.7MPopulation Analysis of Pseudomonas aeruginosa VirulenceR01AI118257 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HAUSER, ALAN R · 2016 to 2025
$4.9MSystems-based pharmacologic modelling to elucidate beta-lactam clinical pharmacodynamics and define optimal dosing regimens in severe pneumoniaR01AI158530 · NIAID · MIDWESTERN UNIVERSITY · PI Nathaniel James Rhodes · 2022 to 2026
$3.4MNIAID NIH HHS R01 AI118257NIAID NIH HHS R01 AI158530NIAID NIH HHS U19 AI135964NIH HHS R01AI118257NIH HHS R01AI158530NIH HHS U19AI135964
6 · The paper itselfAbstract
The prevalence of non-susceptibility to ceftolozane-tazobactam (C/T) among
Indexed as
Anti-Bacterial Agentsbeta-LactamasesCephalosporinsPseudomonas aeruginosaTazobactamBacterial ProteinsDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsPseudomonas InfectionsThird Generation CephalosporinsWhole Genome SequencingAnti-Bacterial AgentsBacterial Proteinsbeta-lactamase L2beta-Lactamasesceftolozane, tazobactam drug combinationCephalosporinsTazobactamThird Generation Cephalosporinsbioinformaticsceftolozane-tazobactamresistancewhole-genome sequencingβ-lactamases
Identifiers
PMID42695947
PMCPMC13602457
What OpenQuestion holds
Textmetadata
Read underepoch 390